CJC-1295

CJC-1295 – Long-Acting GHRH Research Peptide

Growth Hormone-Releasing Hormone Analogue for Pituitary Signaling, GH Secretion & IGF-1 Research

CJC-1295 is a synthetic, long-acting analogue of Growth Hormone-Releasing Hormone (GHRH) developed for scientific investigation of pituitary growth hormone secretion, endocrine signaling and the growth hormone–insulin-like growth factor 1 (GH–IGF-1) axis.

CJC-1295 was designed using a modified GHRH peptide sequence combined with a Drug Affinity Complex (DAC) that enables prolonged association with circulating albumin.

This molecular design distinguishes the original CJC-1295 compound from shorter-acting GHRH analogues.

The prolonged pharmacokinetic profile of CJC-1295 has made it an important investigational peptide in studies involving:

• Growth hormone-releasing hormone receptor signaling

• Pituitary endocrine function

• Growth hormone secretion

• IGF-1 regulation

• Hormonal pulsatility

• Peptide pharmacokinetics

• Albumin-binding peptide technology

• Neuroendocrine physiology

Early human clinical studies demonstrated sustained changes in circulating growth hormone and IGF-1 concentrations following administration of investigational CJC-1295 formulations.

However, these findings do not establish CJC-1295 as a clinically effective or approved treatment for muscle growth, fat loss, recovery, longevity or general hormonal optimization.

ICAME Pharmacy CJC-1295 is intended strictly for laboratory research and development purposes. It is not intended for human or veterinary use.

What Is CJC-1295?

CJC-1295 is a modified peptide analogue of the biologically active N-terminal region of human growth hormone-releasing hormone.

Natural GHRH is produced primarily by neurons in the hypothalamus.

Its principal physiological function is to stimulate the anterior pituitary gland to release growth hormone.

Growth hormone subsequently influences multiple tissues and contributes to the regulation of IGF-1 production.

CJC-1295 was developed to investigate whether structural modification of a GHRH-derived peptide could extend its duration of activity.

The original compound incorporates a drug affinity complex designed to interact with circulating albumin, increasing systemic exposure compared with short-acting GHRH-derived peptides.

This makes CJC-1295 relevant to research involving both endocrine physiology and long-acting peptide design.

CJC-1295 and Growth Hormone-Releasing Hormone

Growth Hormone-Releasing Hormone (GHRH) is an endogenous hypothalamic peptide hormone.

It acts on specialized cells in the anterior pituitary gland known as somatotrophs.

GHRH binds to the GHRH receptor (GHRHR), a G protein-coupled receptor involved in regulating growth hormone secretion.

The physiological pathway can be summarized as follows:

Hypothalamus

↓

GHRH Release

↓

GHRH Receptor Activation

↓

Anterior Pituitary Somatotrophs

↓

Growth Hormone Secretion

↓

IGF-1 Production and Endocrine Signaling

This system is regulated by additional factors, including somatostatin, ghrelin-associated signaling and feedback from growth hormone and IGF-1.

CJC-1295 has been investigated as an experimental means of prolonging stimulation of this endocrine pathway.

How Does CJC-1295 Work?

CJC-1295 acts as a GHRH receptor agonist.

The peptide interacts with GHRH receptors expressed by pituitary somatotrophs.

Activation of these receptors stimulates intracellular signaling pathways associated with growth hormone secretion.

The GHRH receptor primarily couples to Gs proteins, which stimulate adenylyl cyclase activity.

This increases intracellular cyclic adenosine monophosphate (cAMP) and activates downstream signaling mechanisms.

Simplified Mechanism of Action

CJC-1295

↓

GHRH Receptor (GHRHR)

↓

Gs Protein Activation

↓

Adenylyl Cyclase

↓

Increased cAMP Signaling

↓

Protein Kinase A-Associated Pathways

↓

Pituitary Growth Hormone Secretion

↓

GH–IGF-1 Axis Signaling

The activity of this pathway depends on the physiological condition of the pituitary gland and the broader endocrine regulatory environment.

CJC-1295 does not replace growth hormone itself; it is designed to stimulate endogenous hormone secretion through GHRH-associated signaling.

What Is the Drug Affinity Complex (DAC)?

The Drug Affinity Complex (DAC) is one of the defining structural features of the original CJC-1295 molecule.

It was developed to extend the circulating duration of peptide activity.

Conventional peptide hormones are often cleared rapidly because of enzymatic degradation and renal elimination.

The DAC component of CJC-1295 contains a reactive chemical group designed to form a covalent bond with circulating albumin.

Albumin is a major plasma protein that contributes to the transport and distribution of numerous endogenous and pharmaceutical molecules.

By associating with albumin, CJC-1295 exhibits a substantially prolonged pharmacokinetic profile.

Research Significance of DAC Technology

Albumin association

Extended systemic exposure

Reduced rapid peptide clearance

Prolonged receptor-associated activity

Long-acting peptide pharmacology

Peptide–protein conjugation research

The albumin-binding design of CJC-1295 has made it relevant to the broader development of long-acting peptide technologies.

CJC-1295 With DAC vs. Without DAC

A critical distinction in CJC-1295 research is the difference between the original albumin-binding compound and products marketed as CJC-1295 without DAC.

The latter are commonly associated with Modified GRF (1–29), a related but chemically distinct GHRH analogue.

These compounds should not be treated as interchangeable.

The original published CJC-1295 clinical studies investigated the long-acting DAC-containing molecule.

Those results should not automatically be applied to Modified GRF (1–29).

Accurate product identification is therefore essential for scientific documentation.

CJC-1295 and Growth Hormone Secretion

Growth hormone is secreted by the anterior pituitary gland.

Its secretion is regulated by hypothalamic hormones, metabolic conditions, sleep-related physiology and endocrine feedback mechanisms.

CJC-1295 has been investigated for its ability to stimulate endogenous growth hormone secretion over a prolonged period.

Early clinical studies in healthy adults demonstrated sustained increases in circulating growth hormone concentrations.

These findings provided evidence that prolonged GHRH receptor stimulation could influence the GH–IGF-1 endocrine axis.

However, increased circulating growth hormone is a pharmacodynamic finding.

It does not independently establish improvements in strength, physical performance, body composition or health outcomes.

CJC-1295 and IGF-1 Research

Insulin-Like Growth Factor 1 (IGF-1) is an important mediator of growth hormone-associated endocrine signaling.

Growth hormone stimulates IGF-1 production in several tissues, particularly the liver.

IGF-1 participates in biological processes associated with growth, cellular signaling and metabolic regulation.

CJC-1295 research has examined how prolonged GHRH receptor activation influences circulating IGF-1 concentrations.

Investigated pathways include:

GH-dependent IGF-1 production

Endocrine feedback regulation

IGF-1-associated cellular signaling

Pituitary–hepatic communication

Hormonal response duration

Neuroendocrine adaptation

The GH–IGF-1 axis is biologically complex, and sustained changes in hormone concentrations may have both physiological and safety implications.

CJC-1295 and Hormonal Pulsatility

Growth hormone is normally released in pulses rather than at a constant rate.

This pulsatile secretion is an important feature of normal endocrine physiology.

GH pulses are influenced by the interaction between GHRH, somatostatin and other regulatory factors.

One concern associated with prolonged stimulation of the GHRH receptor is whether it alters the normal pattern of GH secretion.

A published human study investigated this question following exposure to CJC-1295.

The researchers observed increased growth hormone secretion while the pulsatile pattern was preserved.

The findings suggested that continuous GHRH receptor stimulation could increase baseline GH secretion without completely eliminating normal secretory pulsatility.

This makes CJC-1295 particularly relevant to research examining the relationship between hormone secretion patterns and sustained receptor activation.

Human Clinical Research on CJC-1295

A study published in the Journal of Clinical Endocrinology & Metabolism in 2006 evaluated the pharmacokinetics, pharmacodynamic activity and short-term safety of CJC-1295 in healthy adults.

The investigation included randomized, placebo-controlled, double-blind studies.

Participants were monitored for changes in circulating growth hormone and IGF-1 concentrations.

Following a single administration of the investigational DAC-containing formulation, researchers reported:

Growth Hormone: Mean plasma concentrations increased approximately 2- to 10-fold for six days or longer.

IGF-1: Mean plasma concentrations increased approximately 1.5- to 3-fold for nine to eleven days.

Estimated Half-Life: Approximately 5.8–8.1 days.

These findings demonstrated prolonged endocrine activity in the investigated population.

However, the trials were relatively small and focused primarily on hormonal biomarkers and short-term pharmacological outcomes.

They did not establish long-term clinical efficacy or safety for general human use.

CJC-1295 and Pituitary Function Research

The anterior pituitary gland is a central component of the endocrine system.

Its somatotroph cells produce and release growth hormone in response to multiple physiological signals.

CJC-1295 research is relevant to understanding:

• GHRH receptor activation

• Somatotroph signaling

• cAMP-dependent pathways

• Growth hormone secretion

• Endocrine feedback

• Hormonal pulsatility

• Pituitary responsiveness

• Long-acting receptor stimulation

These pathways are important in the study of neuroendocrine regulation and growth hormone physiology.

CJC-1295 and Peptide Pharmacokinetics

Pharmacokinetics describes how a substance is absorbed, distributed, metabolized and eliminated.

Peptides often present challenges because of their susceptibility to enzymatic degradation and relatively rapid clearance.

CJC-1295 was developed to address some of these limitations through albumin-binding technology.

Its design has been investigated in relation to:

Peptide stability

Albumin conjugation

Systemic exposure

Elimination half-life

Pharmacodynamic duration

Peptide–protein interactions

These properties make CJC-1295 an important example of long-acting peptide engineering.

CJC-1295 and Metabolic Research

The growth hormone–IGF-1 axis participates in the regulation of several metabolic processes.

These include:

Glucose metabolism

Lipid metabolism

Protein turnover

Energy balance

Endocrine signaling

Tissue growth and maintenance

Because CJC-1295 influences GH and IGF-1 concentrations in experimental human studies, it is relevant to investigations of endocrine metabolic pathways.

However, CJC-1295 has not been established as an effective or safe intervention for fat loss, metabolic optimization or muscle development.

Research into hormonal responses should not be confused with demonstrated improvements in clinical outcomes.

CJC-1295 and Skeletal Muscle Biology

Growth hormone and IGF-1 participate in biological processes relevant to skeletal muscle physiology.

These processes include cellular signaling, tissue maintenance and protein metabolism.

CJC-1295 may be of interest in experimental studies examining the relationship between the GH–IGF-1 axis and skeletal muscle biology.

Research topics include:

Growth hormone signaling

IGF-1-associated pathways

Muscle-cell biology

Protein metabolism

Endocrine regulation

Tissue adaptation

However, published CJC-1295 studies measuring hormone concentrations do not establish that the compound increases muscle mass, strength or athletic performance in humans.

CJC-1295 and Body Composition Research

Body composition is influenced by numerous physiological systems, including nutritional status, physical activity, insulin signaling and endocrine regulation.

Growth hormone has biological effects relevant to lipid metabolism and body composition.

CJC-1295 has consequently attracted interest in experimental research examining the GH–IGF-1 axis.

However, evidence demonstrating sustained hormone elevation is not equivalent to evidence of meaningful body-fat reduction or improved body composition.

Controlled clinical outcome studies would be required to establish such effects.

CJC-1295 should therefore not be presented as a clinically proven fat-loss or body-recomposition compound.

CJC-1295 and Sleep-Related Endocrine Research

Growth hormone secretion exhibits relationships with sleep physiology, particularly slow-wave sleep.

This relationship has generated interest in the interaction between GHRH signaling and sleep-associated endocrine processes.

CJC-1295 may be relevant to research investigating:

GH secretion patterns

Circadian endocrine regulation

Sleep-associated hormone release

Hypothalamic–pituitary signaling

Neuroendocrine feedback

However, there is insufficient clinical evidence to establish CJC-1295 as an effective treatment for insomnia, sleep quality or sleep-related disorders.

CJC-1295 and Aging Biology

Growth hormone and IGF-1 signaling are frequently investigated in the context of aging biology.

Their activity changes throughout the lifespan and interacts with multiple metabolic and cellular pathways.

CJC-1295 has attracted attention because of its ability to influence circulating GH and IGF-1 concentrations.

However, aging biology is complex.

Higher growth hormone or IGF-1 concentrations do not necessarily indicate healthier aging.

There is no established clinical evidence that CJC-1295 reverses aging, extends human lifespan or prevents age-associated disease.

Its relevance should be described as endocrine and aging-related pathway research, rather than proven anti-aging activity.

CJC-1295 and GHRH Receptor Pharmacology

The GHRH receptor belongs to the class B family of G protein-coupled receptors.

Its activation initiates intracellular signaling associated with pituitary growth hormone release.

CJC-1295 research is relevant to understanding:

• Peptide–receptor interactions

• GHRH receptor agonism

• Gs protein signaling

• Adenylyl cyclase activation

• cAMP signaling

• Pituitary endocrine responses

• Receptor stimulation duration

• Long-acting peptide pharmacology

These mechanisms make CJC-1295 a useful subject for research into peptide-based endocrine signaling.

CJC-1295 and Ipamorelin Research

CJC-1295 is sometimes discussed alongside ipamorelin, a synthetic growth hormone secretagogue.

The two compounds have different principal receptor targets.

CJC-1295 acts through GHRH receptor-associated pathways.

Ipamorelin acts primarily through the growth hormone secretagogue receptor, GHSR1a.

These receptor systems participate in the broader regulation of growth hormone secretion.

Researchers may investigate interactions between GHRH-associated and ghrelin receptor-associated signaling.

However, the existence of complementary receptor pathways does not establish that combining the compounds is safe, clinically effective or beneficial.

Published findings from CJC-1295 monotherapy studies should not be presented as evidence for the safety or efficacy of CJC-1295–ipamorelin combinations.

CJC-1295 vs. Other GHRH-Related Peptides

Although these compounds are associated with growth hormone regulation, they differ in molecular structure, receptor pharmacology, pharmacokinetics and clinical evidence.

They should not be treated as interchangeable.

Safety and Scientific Limitations

CJC-1295 has demonstrated pharmacological activity in small human studies.

However, the available clinical evidence is insufficient to establish long-term safety or therapeutic efficacy.

Important considerations include:

Sustained GH and IGF-1 elevation

Potential effects on glucose regulation

Fluid retention and other endocrine effects

Uncertain long-term safety

Limited clinical outcome data

Differences between research-grade and pharmaceutical formulations

Potential product identity and purity concerns

Changes in the GH–IGF-1 axis may have consequences beyond the intended experimental endpoint.

Therefore, short-term tolerability findings should not be interpreted as proof of long-term safety.

CJC-1295 is not an approved general-purpose treatment for growth hormone enhancement, muscle development, weight management, recovery or longevity.

Potential Research Applications

CJC-1295 may be of interest in controlled scientific investigations involving:

• Growth hormone-releasing hormone biology

• GHRH receptor signaling

• Pituitary function

• Growth hormone secretion

• IGF-1 regulation

• Hypothalamic–pituitary signaling

• Neuroendocrine physiology

• Hormonal pulsatility

• Endocrine feedback

• Peptide pharmacokinetics

• Albumin-binding peptide technology

• Drug affinity complex research

• Peptide–protein conjugation

• cAMP-associated signaling

• Growth hormone-associated metabolism

• Skeletal muscle endocrine biology

• Aging-related endocrine pathways

• Experimental peptide pharmacology

Its principal scientific significance lies in the investigation of prolonged GHRH receptor stimulation and the resulting endocrine responses.

CJC-1295 Research Overview

Compound Name: CJC-1295

Classification: Synthetic GHRH Analogue

Original Research Form: CJC-1295 With DAC

Principal Molecular Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)

Primary Research Pathway: GH–IGF-1 Axis

Pharmacological Feature: Long-Acting Albumin Association

Primary Research Fields: Endocrinology / Pituitary Signaling / Peptide Pharmacokinetics

Clinical Status: Investigational; no established approved therapeutic indication

Product Information

Product Name: CJC-1295

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Growth Hormone-Releasing Hormone Analogue

Research Area: GHRH Receptor Biology / Growth Hormone Signaling / IGF-1 Research

Intended Use: Laboratory Research & Development Only

The exact identity of the supplied material must be verified before publication.

In particular, the product documentation should clearly establish whether the material is:

CJC-1295 With DAC

or

Modified GRF (1–29), Commonly Marketed as CJC-1295 Without DAC

These are distinct molecular entities.

Batch-specific documentation should include, where applicable:

• Verified peptide identity and sequence

• Presence or absence of DAC

• Chemical form and counterion

• Molecular weight

• Analytical purity

• Analytical methodology

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

Claims about prolonged albumin binding and multi-day pharmacokinetics should not be applied to a no-DAC product.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, muscle-development, weight-management, hormone-enhancement, recovery, performance-enhancing or anti-aging purposes. Not for direct administration to humans or animals.

CJC-1295 is a pharmacologically active investigational peptide.

Clinical findings involving investigational pharmaceutical formulations should not be interpreted as evidence of safety, efficacy or pharmaceutical equivalence for ICAME Pharmacy research materials.

Information presented on this page is intended solely for scientific and educational purposes and should not be interpreted as medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to contemporary areas of peptide science, molecular biology, endocrinology, receptor pharmacology, metabolic research and experimental life sciences.

Product information is presented with an emphasis on responsible research use, scientific transparency, clear product identification and professional research applications.

For batch-specific documentation, analytical information and product inquiries, please contact ICAME Pharmacy.